GM-CSF: A double-edged sword in cancer immunotherapy
A Kumar, A Taghi Khani, A Sanchez Ortiz… - Frontiers in …, 2022 - frontiersin.org
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a cytokine that drives the
generation of myeloid cell subsets including neutrophils, monocytes, macrophages, and …
generation of myeloid cell subsets including neutrophils, monocytes, macrophages, and …
[HTML][HTML] Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
SS Neelapu, S Tummala, P Kebriaei… - Nature reviews Clinical …, 2018 - nature.com
Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor
(CAR) is rapidly emerging as a promising new treatment for haematological and non …
(CAR) is rapidly emerging as a promising new treatment for haematological and non …
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Genetically engineered T cells expressing a chimeric antigen receptor (CAR) are rapidly
emerging a promising new treatment for haematological and non-haematological …
emerging a promising new treatment for haematological and non-haematological …
Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study
Acute lymphoblastic leukemia (ALL) is a cancer-specific lymphoid cell. Induction and
consolidation chemotherapy alone or in combination with different therapeutic approaches …
consolidation chemotherapy alone or in combination with different therapeutic approaches …
GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches
Therapeutics against coronavirus disease 2019 (COVID-19) are urgently needed.
Granulocyte–macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor …
Granulocyte–macrophage colony-stimulating factor (GM-CSF), a myelopoietic growth factor …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
MV Maus, S Alexander, MR Bishop… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Immune effector cell (IEC) therapies offer durable and sustained remissions in significant
numbers of patients with hematological cancers. While these unique immunotherapies have …
numbers of patients with hematological cancers. While these unique immunotherapies have …
CAR-T therapies in solid tumors: opportunities and challenges
G Guzman, MR Reed, K Bielamowicz, B Koss… - Current Oncology …, 2023 - Springer
Abstract Purpose of Review This review will discuss the challenges facing chimeric antigen
receptor (CAR)-T cell application for solid tumors and opportunities to overcome these …
receptor (CAR)-T cell application for solid tumors and opportunities to overcome these …
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
J Wei, Y Liu, C Wang, Y Zhang, C Tong, G Dai… - … and Targeted Therapy, 2020 - nature.com
Chimeric antigen receptor T (CAR T) cell therapy has demonstrated efficacy in the treatment
of haematologic malignancies. However, the accompanying adverse events, the most …
of haematologic malignancies. However, the accompanying adverse events, the most …
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
Z Wang, W Han - Biomarker research, 2018 - Springer
Severe cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen
receptor T cell (CAR-T) therapy can be life-threatening in some cases, and management of …
receptor T cell (CAR-T) therapy can be life-threatening in some cases, and management of …
CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities
JW Fischer, N Bhattarai - Frontiers in Immunology, 2021 - frontiersin.org
Engineered T cell therapies such as chimeric antigen receptor (CAR) expressing T cells
(CAR-T cells) have great potential to treat many human diseases; however, inflammatory …
(CAR-T cells) have great potential to treat many human diseases; however, inflammatory …